ONP-001 / OmniNano Pharmaceuticals - LARVOL DELTA

Dual mechanism nanomedicine targeting drug resistance in pancreatic ductal adenocarcinoma (PDAC) Free (AACRPanCa 2025) - "We comprehensively evaluated the antitumor activity of polymeric micelles encapsulating cyclopamine and paclitaxel (ONP-001). ONP-001 preferentially delivers CPA and PTX to tumors, modulates the tumor stroma to increase blood flow, and decrease fibrosis and hypoxia, and kills cancer cells, creating a tumor microenvironment that is less supportive of cancer growth. ONP-001 significantly extended survival compared to gemcitabine + nab-paclitaxel in a resistant disease model of PDAC, suggesting potential for clinical translation. Ongoing studies are exploring synergy with immunotherapy and optimal dosing strategies to support IND-enabling development."

Fibrosis • Immunology • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • KRAS

Development and comprehensive preclinical evaluation of dual-drug polymeric micelles ONP-001 for PDAC and HCC (AACR 2025) - "This study comprehensively evaluated the mechanisms of polymeric micelles co-encapsulating cyclopamine (CPA) and paclitaxel (PTX) (M-CPA/PTX, ONP-001) and the effectiveness against HCC and PDAC...Studies in the transgenic HCC model also confirmed significantly greater antitumor efficacy for ONP-001, with no observed hepatotoxicity, compared to sorafenib treatment. ONP-001 was an effective therapeutic strategy for PDAC and HCC, targeting CSCs, modulating the stroma, and enhancing immunotherapy, at 5.0 mg/kg, TIW, with enhanced benefits when in combination regimens. ONP-001 was an effective therapeutic strategy for PDAC and HCC, targeting CSCs, modulating the stroma, and enhancing immunotherapy, at 5.0 mg/kg, TIW, with enhanced benefits when in combination regimens. Ongoing studies will further characterize the pharmacokinetics, tumor uptake and biodistribution of both drugs. The data supports further development of ONP-001 for potential future clinical development."

IO biomarker • Preclinical • Hepatocellular Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • IL15 • IL33 • KRAS